On the GARDP website, find information about their strategic approach to addressing antimicrobial resistance (AMR). Identify the three main criteria that guide GARDP's disease area strategy and briefly describe each. Additionally, state the core characteristic of GARDP’s unique antibiotic R&D partnership model.
Navigate to gardp.org. Explore the main navigation to find sections related to GARDP's work or strategy (e.g., 'Our programmes' or 'Our work'). Locate and navigate to the 'GARDP Strategy 2024-2028' page. On this page, identify the three criteria that form GARDP's disease area strategy and their descriptions. Also, locate the key characteristic of GARDP’s unique antibiotic R&D partnership model. Extract and present all requested information.
Successfully navigate to the 'GARDP Strategy 2024-2028' page. Accurately list the three main criteria for GARDP's disease area strategy: - Prioritizes serious bacterial infections and sepsis (including neonatal sepsis) and sexually transmitted infections (with a focus on gonorrhoea). - Targets WHO priority pathogens that are responsible for particularly deadly and debilitating drug-resistant infections. - Concentrates its efforts on populations who are disproportionately affected by drug resistance—like newborns, children and women, particularly in low- and middle-income countries. For each criterion, provide a brief and accurate description of its core objective. Identify and state the key characteristic of GARDP's 'unique antibiotic R&D partnership model' as: 'enabling the right antibiotic treatments to be developed and made available to people who need them'.